Adalimumab
Adalimumab is a pharmaceutical drug with 341 clinical trials. Currently 35 active trials ongoing. Historical success rate of 92.9%.
Success Metrics
Based on 235 completed trials
Phase Distribution
Phase Distribution
20
Early Stage
64
Mid Stage
206
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
87.7%
235 of 268 finished
12.3%
33 ended early
35
trials recruiting
341
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)
A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis
Clinical Trials (341)
An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)
A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis
Comparison of the Efficacy of Different Biologic Agents in Preventing Postoperative Endoscopic Recurrence of Crohn's Disease
Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation
Utilization of a Microdevice for Psoriasis and Atopic Dermatitis
Prediction of Treatment Response at 6 Months by Combinatorial Analysis of Serum Biomarkers in Biotherapy Naive SpA
Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Netakimab in Children With Moderate to Severe Plaque Psoriasis
A Study of LAD191 in Adults With Hidradenitis Suppurativa
Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration.
A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Clinical Trial Using Humira in Netherton Syndrome
Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission
Treatment Tapering in JIA With Inactive Disease
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 341